Integra Lifesciences Holdings Corp (NASDAQ:IART) Director Keith Bradley sold 15,658 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were sold at an average price of $55.00, for a total transaction of $861,190.00. Following the transaction, the director now directly owns 37,074 shares of the company’s stock, valued at $2,039,070. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Shares of Integra Lifesciences Holdings Corp (NASDAQ IART) opened at $53.68 on Wednesday. The firm has a market cap of $4,313.12, a P/E ratio of 30.36, a PEG ratio of 1.75 and a beta of 0.67. Integra Lifesciences Holdings Corp has a one year low of $40.51 and a one year high of $56.42. The company has a quick ratio of 3.39, a current ratio of 4.49 and a debt-to-equity ratio of 1.26.
Integra Lifesciences (NASDAQ:IART) last issued its quarterly earnings results on Tuesday, February 27th. The life sciences company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.56 by $0.08. Integra Lifesciences had a net margin of 4.52% and a return on equity of 16.35%. The company had revenue of $368.60 million during the quarter, compared to analyst estimates of $362.64 million. During the same period in the prior year, the business posted $0.52 EPS. The business’s revenue for the quarter was up 44.2% compared to the same quarter last year. research analysts anticipate that Integra Lifesciences Holdings Corp will post 1.86 earnings per share for the current year.
A number of research analysts have issued reports on IART shares. UBS Group reissued a “buy” rating and set a $57.00 target price on shares of Integra Lifesciences in a research note on Tuesday, October 31st. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $50.00 price target (up from $48.00) on shares of Integra Lifesciences in a research note on Thursday, November 9th. Oppenheimer set a $58.00 price target on shares of Integra Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, December 12th. Zacks Investment Research lowered shares of Integra Lifesciences from a “hold” rating to a “sell” rating in a research note on Wednesday, December 13th. Finally, Bank of America lowered shares of Integra Lifesciences from a “buy” rating to a “neutral” rating in a research note on Tuesday, January 2nd. One research analyst has rated the stock with a sell rating, ten have issued a hold rating and three have assigned a buy rating to the company’s stock. Integra Lifesciences presently has a consensus rating of “Hold” and a consensus target price of $52.70.
ILLEGAL ACTIVITY NOTICE: This piece of content was first reported by Ticker Report and is owned by of Ticker Report. If you are reading this piece of content on another website, it was illegally copied and republished in violation of US and international copyright & trademark laws. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3228047/insider-selling-integra-lifesciences-holdings-corp-iart-director-sells-15658-shares-of-stock.html.
Integra Lifesciences Company Profile
Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.
Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.